| Autor: |
Aguilar‐Calderón, P. E., Brussolo‐Marroquin, E., Riojas‐Hernández, E. D., Gómez‐Flores, M., Ocampo‐Candiani, J., Ocampo‐Garza, S. S. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Aug2024, Vol. 38 Issue 8, pe708-e710, 3p |
| Abstrakt: |
This article discusses the use of off-label biologic treatments for refractory inflammatory scarring alopecia. Scarring alopecias are a group of diseases that result in permanent hair loss. The article provides a review of different off-label systemic treatments for conditions such as dissecting cellulitis of the scalp, folliculitis decalvans, lichen planopilaris, and frontal fibrosing alopecia. The treatments mentioned include adalimumab, guselkumab, secukinumab, risankizumab, tildrakizumab, and certolizumab. The article concludes that while these case reports offer hope for affected patients, controlled clinical trials are needed to fully understand the effectiveness and potential side effects of these treatments. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text